Consolidated Statement of Income - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenues
Revenues	$ 39,211	$ 32,218	$ 25,542
Costs and operating expenses:
Selling, general and administrative expenses	8,007	6,930	6,144
Research and development expenses	1,406	1,181	1,003
Restructuring and other costs (income)	197	99	(413)
Total costs and operating expenses	29,183	24,424	20,948
Operating income	10,028	7,794	4,594
Interest income	43	65	224
Interest expense	(536)	(553)	(676)
Other income/(expense)	(694)	(76)	(70)
Income before income taxes	8,841	7,230	4,072
Provision for income taxes	(1,109)	(850)	(374)
Equity in (losses) earnings of unconsolidated entities	(4)	(3)	0
Net income	7,728	6,377	3,698
Less: net income attributable to noncontrolling interests and redeemable noncontrolling interest	3	2	2
Net income attributable to Thermo Fisher Scientific Inc.	$ 7,725	$ 6,375	$ 3,696
Earnings per share attributable to Thermo Fisher Scientific Inc.
Basic (in dollars per share)	$ 19.62	$ 16.09	$ 9.24
Diluted (in dollars per share)	$ 19.46	$ 15.96	$ 9.17
Weighted average shares
Basic (in shares)	394	396	400
Diluted (in shares)	397	399	403
Product [Member]
Revenues
Revenues	$ 30,361	$ 25,306	$ 19,496
Costs and operating expenses:
Cost of revenues	13,594	11,407	10,037
Service [Member]
Revenues
Revenues	8,850	6,912	6,046
Costs and operating expenses:
Cost of revenues	$ 5,979	$ 4,807	$ 4,177